Friday, 23 Mar 2018

You are here

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on

  1. FDA has announced Arthritis Advisory Hearing on Aug 2nd (Sirukumab in RA) and Aug 3rd (Tofacitinib in PsA)
  2. Metanalyses suggest a decreasing risk of CVD in rheumatoid arthritis after 2000
  3. Monitoring IgG4 related disease w/ ESR CRP IgG4 levels not reliable. but imaging w/ 18F-FDG PET/CT reflects activity
  4. SLE nephritis & 64 controls show pregnancy on lupus nephritis does not increase SLE flares, renal outcomes or CKD
  5. NEJM Study >73K shows Improved diet quality over 12 yrs associated w/ decreased risk of death (7-17% less mortality)
  6. Baricitinib gets market approval in Japan ( & NICE recommends Oluminant for UK approval (
  7. IOM review shows uninsured have poorer health & shortened lives;Concludes health insurance reduces the risk of death
  8. Warnings section of the OTEZLA (apremilast) label updated to include risk of severe diarrhea, nausea, and vomiting.
  9. Population study of 40K Dutch finds ACPA positivity in 1%; assoc w/ age, smoking, female & RA;but only 15-20% had RA
  10. increased pregnancy-induced type I IFN-inducible gene expression observed in preg RA women who improved during preg
  11. Orencia Approved for Use in Psoriatic Arthritis  
  12. Alendronate Use in Steroid Treated Patients Lowers the Risk of Hip Fracture
  13. Withdrawal of TNF Inibitors Fails in Most RA Patients
  14. Statins Improve Survival in Ankylosing Spondylitis


The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Jack-I may have mentioned this in the past but again wonder if the improvement of CVD in RA patients may be a result of the markedly decreased use of NSAIDs as background therapy in RA patients on cDMARDs and bDMARDs since 2000.-D,Knapp
I think yours is a very valid point as research has shown a definite decline in NSAID use after the VIOXX/Cox-2 FDA hearing. But are rheums using more low dose prednisone instead? Researchers should control for these issues in their analyses. Good Point! JC

More Like This

The RheumNow Week in Review - 23 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

The CDC estimates that physician-diagnosed arthritis affects 54 million of adults in the United States with an annual cost of approximately $300 billion annually.

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

ACR Responds to Association Health Plans Proposed Rule

In comments submitted today to the US Department of Labor in response to its Association Health Plans (AHP) proposed rule, the American College of Rheumatology urged Administration officials to protect essential health benefits and other consumer protections that make it possible for individuals living with rheumatic diseases to access comprehensive and affordable healthcare.